PrestonDSteenMD

Oncology • Fargo, ND

Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative

Clinical Professor of Medical Oncology, University of North Dakota School of Medicine and Health Sciences

Join to view full profile

Dr. Steen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Steen's full profile

Already have an account?

Office
820 4th Street N
Fargo, ND 58122
Phone+1 701-234-6161

Fax+1 701-234-7139
Is this information wrong?

Education & Training

University of Utah HealthFellowship, Hematology and Medical Oncology, 1987 - 1990
Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 1984 - 1987
University of Minnesota Medical SchoolClass of 1984

Certifications & Licensure

ND State Medical License 1990 - 2025
MN State Medical License 1990 - 2024
UT State Medical License 1987 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors for Cancer Castle Connolly, 2010-2013, 2015
Fellow American College of Physicians American College of Physicians, 1995
America's Top Doctors Castle Connolly, 2011-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Join now to see all

Clinical Trials

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary Start of enrollment: 2004 Feb 01
Completed
Phase 2
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2006 Mar 24
Completed
Phase 1, Phase 2
Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers Start of enrollment: 2006 Apr 01
Completed
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Start of enrollment: 2008 Feb 01
Completed
Phase 3
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection Start of enrollment: 2006 Jun 01
Completed
Phase 3
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Start of enrollment: 2006 Jul 01
Completed
Phase 3
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Mar 01
Completed
Phase 1, Phase 2
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer Start of enrollment: 2008 Feb 01
Active, not recruiting
Phase 3
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Acute Pain Caused by Paclitaxel in Patients With Cancer Start of enrollment: 2009 Feb 01
Completed
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1, Phase 2
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary Start of enrollment: 2009 Sep 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2009 Nov 01
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma Start of enrollment: 1995 Dec 01
Completed
Study of Tissue and Blood Samples From Patients With High-Grade Glioma Start of enrollment: 1995 Nov 01
Completed
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2010 Jan 01
Terminated
Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Start of enrollment: 2010 Aug 11
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Start of enrollment: 2010 Dec 01
Completed
Phase 3
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy Start of enrollment: 2011 Apr 01
Completed
Phase 3
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 3
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Start of enrollment: 2011 Jul 01
Completed
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Start of enrollment: 2012 Mar 16
Completed
Phase 2
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Start of enrollment: 2012 Nov 01
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
Active, not recruiting
Phase 2, Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer Start of enrollment: 2020 Jun 17
Recruiting
Phase 2, Phase 3
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
Active, not recruiting
Phase 2
A Study of miRNA 371 in Patients With Germ Cell Tumors Start of enrollment: 2020 Jul 28
Recruiting
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Start of enrollment: 2020 Dec 09
Terminated
Phase 3
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Start of enrollment: 2019 Dec 17
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.
Nicole L Stout, Daniel Nikcevich, Tara O Henderson, Preston Steen, Matthias Weiss, Steven Ades, Tammie Mlodozyniec, Amy Koffarnus, Betsy Barnick, Electra D Paskett> ;Journal of Clinical Oncology. 2024 Feb 27
1 citations
Integrin β1 is a key determinant of the expression of angiotensin-converting enzyme 2 (ACE2) in the kidney epithelial cells.
Md Saimon Mia, Delowar Hossain, Emerson Woodbury, Sean Kelleher, Riya J Palamuttam, Reena Rao, Preston Steen, Yagna Pr Jarajapu, Sijo Mathew> ;European Journal of Cell Biology. 2023 Jun 1
10 citations
β-Sheet Richness of the Circulating Tumor-Derived Extracellular Vesicles for Noninvasive Pancreatic Cancer Screening.
Komila Rasuleva, Santhalingam Elamurugan, Aaron Bauer, Mdrakibhasan Khan, Qian Wen, Zhaofan Li, Preston Steen, Ang Guo, Wenjie Xia, Sijo Mathew, Rick J. Jansen, Dali Sun> ;ACS Sensors. 2021 Nov 30
1 citations
Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program
Jonathan Bleeker, Christopher J. Sumey, Steven F. Powell, Preston D. Steen, Michael D. Keppen, Michele Lohr, Thavam Thambi-Pillai, Peter Kurniali, Miroslaw Mazurczak, ...> ;Surgery Open Science. 2020 Jul 29
22 citations
A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial
Aminah Jatoi, Preston D. Steen, Pamela J. Atherton, Dennis F. Moore, Kendrith M. Rowland, Nguyet A. Le-Lindqwister, C. S. Adonizio, Anthony J. Jaslowski, Jeff A. Sloan...> ;Annals of Oncology. 2017 Aug 1
87 citations
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECO...
Joel W. Neal, Suzanne E. Dahlberg, Heather A. Wakelee, Seena C. Aisner, Michaela Bowden, Ying Huang, David P. Carbone, Gregory J Gerstner, Rachel E Lerner, Jerome L Ru...> ;The Lancet. Oncology. 2016 Dec 1
39 citations
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
Harry H. Yoon, Nathan R. Foster, Jeffrey P. Meyers, Preston D. Steen, DW Visscher, Raji Pillai, Debra M. Prow, C. M. Reynolds, Benjamin T. Marchello, Rex B. Mowat, Bas...> ;Annals of Oncology. 2016 Feb 1
32 citations
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Julian R. Molina, Nathan R. Foster, Thanyanan Reungwetwattana, Garth D. Nelson, Andrew V. Grainger, Preston D. Steen, Philip J. Stella, Randolph S. Marks, John Wright,...> ;Lung Cancer. 2014 Aug 1
6 citations
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Tr...
Winston Tan, Amylou C. Dueck, Patrick J. Flynn, Preston D. Steen, D. M. Anderson, Kendrith M. Rowland, Donald W. Northfelt, E. A. Perez> ;Annals of Oncology. 2013 Oct 1
126 citations
Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire
Ellen M. Lavoie Smith, Debra L. Barton, Rui Qin, Preston D. Steen, Neil K. Aaronson, Charles L. Loprinzi> ;Quality of Life Research. 2013 Mar 30
4 citations
Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial
Shernan G. Holtan, Preston D. Steen, Nathan R. Foster, Charles Erlichman, Fabiola Medeiros, Matthew M. Ames, Stephanie L. Safgren, David L. Graham, Robert J. Behrens, ...> ;Plos One. 2012 Jul 17
15 citations
Hepatic Arterial Infusion and Systemic Chemotherapy after Multiple Metastasectomy in Patients with Colorectal Carcinoma Metastatic to the Liver: A North Central Cancer...
John S. Bolton, Michael J. O'Connell, Michelle R. Mahoney, Gist H. Farr, Tom R. Fitch, William J. Maples, David M. Nagorney, Joseph Rubin, Jyotsna Fuloria, Preston D. ...> ;Clinical Colorectal Cancer. 2012 Mar 1
North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) ...
Kim GP, Foster NR, Haddock MG, Bollinger JW, Dakhil SR, Behrens RJ, Flynn PJ, Steen PD, Bury MJ, Stella PJ, Alberts SR> ;J. Clin. Oncol.. 2012-02-01
46 citations
A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7.
Sandhya Pruthi, R. Qin, Shelby A. Terstreip, Heshan Liu, Charles L. Loprinzi, Tushar R.C. Shah, Kenneth F. Tucker, Shaker R. Dakhil, Martin J. Bury, Robert L. Carolla,...> ;Menopause. 2012 Jan 1
The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7.
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL> ;J. Clin. Oncol.. 2011-06-20
The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7.
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL> ;J. Clin. Oncol.. 2011-05-20
6 citations
Evaluation of Methadone Absorption After Topical Administration to Hospice Patients
Robert K. Sylvester, Caroline Schauer, John M. Thomas, Preston D. Steen, Alan Weisenberger> ;Journal of Pain and Symptom Management. 2011 May 1
15 citations
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients
Robert K. Sylvester, Preston D. Steen, John M. Tate, Minesh Mehta, Ryan J. Petrich, Alexander Berg, Jill M. Kolesar> ;Anti-Cancer Drugs. 2011 Jan 1
34 citations
A Front-Line Window of Opportunity Phase 2 Study of Sorafenib in Patients With Advanced Nonsmall Cell Lung Cancer: North Central Cancer Treatment Group Study N0326
Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh G. Nair Md, Sumithra J. Mandrekar, Steven E. Schild, ...> ;Cancer. 2010 Dec 15
3 citations
Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423.
Cheng E. Chee, James R. Jett, Albert M. Bernath, Nathan R. Foster, Garth D. Nelson, Julian R. Molina, Daniel A. Nikcevich, Preston D. Steen, Patrick J. Flynn, Kendrith...> ;Cancer. 2010 May 15
Does efficacy of non-estrogenic therapies for hot flashes among women vary by breast cancer history and tamoxifen use? A pooled analysis.
Bardia A, Novotny PJ, Sloan JA, Barton DL, Steen PD, Watson C, Christensen B, Loprinzi CL> ;J. Clin. Oncol.. 2008-05-20
Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial.
Holtan SG, Foster NR, Erlichman CE, Aubry M, Ames MM, Safgren S, Steen PD, Morton RF, Graham D, Goetz MP> ;J. Clin. Oncol.. 2008-05-20
Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study.
Jett JR, Bernath AM, Foster NR, Molina JR, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM, Fitch TR, Adjei AA> ;J. Clin. Oncol.. 2008-05-20
20 citations
Patient Assessment of Bowel Function During and After Pelvic Radiotherapy: Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial
Michael G. Haddock, Jeff A. Sloan, John W. Bollinger, Gamini S. Soori, Preston D. Steen, James A. Martenson> ;Journal of Clinical Oncology. 2007 Apr 1
19 citations
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
Cynthia X. Ma, Preston D. Steen, Kendrith M. Rowland, R. D. Niedringhaus, Tom R. Fitch, John W. Kugler, David W. Hillman, E. A. Perez, James N. Ingle, Alex A. Adjei> ;Annals of Oncology. 2006 Feb 1
Join now to see all

Grant Support

Sanford Community Cancer ConsortiumNational Cancer Institute2011
Meritcare Hospital Community Clinical Oncology ProgramNational Cancer Institute2007–2010
Meritcare Hospital Community Clinical Oncology ProgramNational Cancer Institute2003–2007
Model Palliative Care Curriculum For Medical StudentsNational Cancer Institute1994–1996